Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) has requested withdrawal of its Registration Statement on Form S-1 (File No. 333-283910) with the SEC. The S-1, originally filed December 18, 2024 and last amended June 3, 2025, covered a planned public offering the company no longer intends to pursue at this time.
The Registration Statement was never declared effective, and no securities were sold in connection with the proposed offering. The company notes this announcement is not an offer or solicitation to buy or sell securities.
AI-generated analysis. Not financial advice.
Positive
- No securities were sold under the withdrawn Form S-1, avoiding share dilution
- Registration Statement on Form S-1 was not declared effective, limiting offering-related obligations
Negative
- Company has withdrawn Form S-1 for a planned public offering
- No public offering will proceed under the withdrawn Registration Statement at this time
News Market Reaction – COSM
On the day this news was published, COSM gained 0.13%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $23K to the company's valuation, bringing the market cap to $17.54M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COSM was down 7.64% while peers were mixed: SNYR and ZYXI showed double-digit declines, YI was modestly lower, EDAP was up, and QIPT was flat. Moves do not point to a unified sector trend.
Previous Crypto Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Revenue projection | Positive | -7.6% | Projected over $3.2M incremental U.S. revenue from Fort18 within 12–18 months. |
| May 06 | Product launch | Positive | -0.8% | Introduced Fort18 in U.S. men’s wellness with supportive clinical research data. |
| Apr 30 | Revenue projection | Positive | +2.5% | Projected over $2.5M incremental U.S. revenue from Cur18 within 12–18 months. |
| Apr 17 | Product launch | Positive | +0.1% | Planned U.S. Cur18 launch with patented curcumin and enhanced bioavailability data. |
| Apr 13 | Commercial order | Positive | +8.5% | Received third Pharmalink order, lifting cumulative UAE units to 270,000. |
Recent ‘crypto’-tagged launches and revenue projections were generally positive in tone, yet three of the last five such releases saw negative next-day moves, suggesting frequent divergence between upbeat operational news and short-term price reactions.
Over the past month, COSM focused its ‘18 Series’ nutraceutical expansion and revenue projections. Announcements on Fort18 and Cur18 highlighted incremental U.S. revenue expectations of over $3.2 million and $2.5 million, alongside clinical data and staged e‑commerce launches. Additional news covered a curated 18-product clinical platform and growing international orders for Sky Premium Life. Against this backdrop of growth initiatives, same-tag news often coincided with volatile or negative one-day price reactions.
Historical Comparison
In the last five ‘crypto’-tagged releases, COSM’s average next-day move was 0.51%, with several positive commercial updates followed by negative or muted trading, making strong reactions to today’s filing withdrawal notable relative to prior patterns.
Tag-specific history shows a progression from international Sky Premium Life orders to U.S. ‘18 Series’ launches and revenue projections for Cur18 and Fort18, building a broader consumer-health footprint while the latest news shifts focus to capital markets strategy via an S-1 withdrawal.
Regulatory & Risk Context
An amended Form S-3/A on April 24, 2026 registered 73,523,716 shares$0.176 conversion/floor price. The company reported 52,617,105 shares outstanding and a pro forma figure of 126,054,324 shares post-offering; proceeds from any resale would go to selling stockholders, not the company. The current press release states the separate Form S-1 will be withdrawn and no securities were sold under that registration.
Market Pulse Summary
This announcement centers on withdrawing a Form S-1 registration that was never declared effective and under which no securities were sold. Capital-raising flexibility remains influenced by an amended Form S-3/A registering 73,523,716 resale shares at a $0.176 conversion floor, with a pro forma share count of 126,054,324. In context of recent ‘18 Series’ launches and revenue projections, investors may watch how future filings, note conversions, and commercialization milestones interact with the evolving share structure.
Key Terms
form s-1 regulatory
registration statement regulatory
u.s. securities and exchange commission regulatory
public offering financial
AI-generated analysis. Not financial advice.
CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a request for withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-283910), originally filed on December 18, 2024 and last amended on June 3, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.
The Registration Statement has not been declared effective and no securities of the Company were sold in connection with the offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire